Tags

Type your tag names separated by a space and hit enter

Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2004 Mar; 10(3):171-7.BB

Abstract

We studied the effect of donor chimerism level on the outcome of donor lymphocyte infusion (DLI) therapy in 42 patients with persistent or relapsed hematologic malignancies after non-T cell-depleted allogeneic hematopoietic cell transplantation. Seventy-five percent of chronic myelogenous leukemia (CML) and 39% of non-CML patients entered remission after DLI therapy. Remission and survival rates were similar for CML patients irrespective of their pre-DLI donor chimerism levels; however, remission occurred sooner in patients with > or =10% pre-DLI donor chimerism. None of the non-CML patients with <10% pre-DLI donor chimerism and 47% of those with > or =10% pre-DLI donor chimerism attained remission. The 2-year survival rates after DLI were 75% for CML and 17% for non-CML patients. We conclude that a low level of donor marrow chimerism is not an adverse prognostic factor for response to DLI in CML patients, but for non-CML patients it may confer worse outcomes. Better methods to augment the response to DLI for patients with hematologic malignancies other than CML that recur after allogeneic hematopoietic cell transplantation are needed, whereas for relapsed CML patients, combination therapies including imatinib mesylate or other promising antileukemic agents may provide outcomes superior to those with DLI alone.

Authors+Show Affiliations

Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis 55455, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14993882

Citation

Chiorean, Elena G., et al. "Donor Chimerism Does Not Predict Response to Donor Lymphocyte Infusion for Relapsed Chronic Myelogenous Leukemia After Allogeneic Hematopoietic Cell Transplantation." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 10, no. 3, 2004, pp. 171-7.
Chiorean EG, DeFor TE, Weisdorf DJ, et al. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004;10(3):171-7.
Chiorean, E. G., DeFor, T. E., Weisdorf, D. J., Blazar, B. R., McGlave, P. B., Burns, L. J., Brown, C., & Miller, J. S. (2004). Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 10(3), 171-7.
Chiorean EG, et al. Donor Chimerism Does Not Predict Response to Donor Lymphocyte Infusion for Relapsed Chronic Myelogenous Leukemia After Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2004;10(3):171-7. PubMed PMID: 14993882.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. AU - Chiorean,Elena G, AU - DeFor,Todd E, AU - Weisdorf,Daniel J, AU - Blazar,Bruce R, AU - McGlave,Philip B, AU - Burns,Linda J, AU - Brown,Charlotte, AU - Miller,Jeffrey S, PY - 2004/3/3/pubmed PY - 2004/10/8/medline PY - 2004/3/3/entrez SP - 171 EP - 7 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol Blood Marrow Transplant VL - 10 IS - 3 N2 - We studied the effect of donor chimerism level on the outcome of donor lymphocyte infusion (DLI) therapy in 42 patients with persistent or relapsed hematologic malignancies after non-T cell-depleted allogeneic hematopoietic cell transplantation. Seventy-five percent of chronic myelogenous leukemia (CML) and 39% of non-CML patients entered remission after DLI therapy. Remission and survival rates were similar for CML patients irrespective of their pre-DLI donor chimerism levels; however, remission occurred sooner in patients with > or =10% pre-DLI donor chimerism. None of the non-CML patients with <10% pre-DLI donor chimerism and 47% of those with > or =10% pre-DLI donor chimerism attained remission. The 2-year survival rates after DLI were 75% for CML and 17% for non-CML patients. We conclude that a low level of donor marrow chimerism is not an adverse prognostic factor for response to DLI in CML patients, but for non-CML patients it may confer worse outcomes. Better methods to augment the response to DLI for patients with hematologic malignancies other than CML that recur after allogeneic hematopoietic cell transplantation are needed, whereas for relapsed CML patients, combination therapies including imatinib mesylate or other promising antileukemic agents may provide outcomes superior to those with DLI alone. SN - 1083-8791 UR - https://www.unboundmedicine.com/medline/citation/14993882/Donor_chimerism_does_not_predict_response_to_donor_lymphocyte_infusion_for_relapsed_chronic_myelogenous_leukemia_after_allogeneic_hematopoietic_cell_transplantation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1083879103003951 DB - PRIME DP - Unbound Medicine ER -